15 Ophthalmology Drugs of Novartis International AG
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
15 Ophthalmology Drugs of Novartis International AG - overview
Location
-, -, Switzerland
Primary Industry
Pharmaceuticals
About
Based in Switzerland, Ophthalmology Drugs of Novartis International AG operates as a provider of ophthalmic drugs used for eye illnesses and diseases. In December 2023, J. B. Chemicals and Pharmaceuticals Limited, a portfolio company of KKR, acquired 15 Ophthalmology Drugs of Novartis International AG for INR 9.
64 billion. The drugs offered by the company include anti-infective, anti-allergy, and glaucoma drugs, and offers ophthalmic drugs used for eye illnesses and diseases.
Current Investors
J. B. Chemicals & Pharmaceuticals Limited
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Verticals
Manufacturing
Company Stage
Add-on
Total Amount Raised
Subscriber access only
15 Ophthalmology Drugs of Novartis International AG - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | 15 Ophthalmology Drugs of Novartis International AG | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.